INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND DENTAL HEALTH
(ISSN: 2454-4191)
www.ijmsdh.org (2026)

Received: 14 Feb 2026
Revised: 19 Mar 2026
Accepted: 21 Apr 2026
Published: 01 May 2026

Page No - 01-05
DOI - 10.55640/ijmsdh-12-05-01

Article Citation: Ivanov, D. S., & Petrova, E. V. (2026). Assessment of Structural and Functional Variability in Successive Autologous Platelet Formulations. International Journal of Medical Science and Dental Health, 12(05), 01-06. https://doi.org/10.55640/ijmsdh-12-05-01

Assessment of Structural and Functional Variability in Successive Autologous Platelet Formulations

Dmitry Sergeevich Ivanov
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sechenov First Moscow State Medical University, Moscow, Russian Federation

Elena Viktorovna Petrova
Department of Conservative Dentistry and Endodontics, Faculty of Dentistry, Saint Petersburg State University, Saint Petersburg, Russian Federation

Abstract

Autologous platelet formulations have become integral to regenerative medicine due to their capacity to deliver a concentrated pool of growth factors, cytokines, and cellular mediators essential for tissue repair and regeneration. Over time, advancements in preparation techniques have resulted in successive generations of platelet-based biomaterials, each exhibiting distinct structural and functional characteristics. This study provides a comprehensive assessment of variability across these formulations, focusing on differences in composition, fibrin architecture, cellular distribution, and biological activity. By synthesizing findings from established literature, the paper examines how preparation protocols—including centrifugation speed, activation methods, and leukocyte inclusion—affect the release kinetics of bioactive molecules and clinical outcomes. Comparative analysis reveals that first-generation formulations are characterized by rapid growth factor release, whereas later formulations demonstrate sustained release and enhanced scaffold properties. Furthermore, the presence of leukocytes and modifications in fibrin structure significantly influence inflammatory responses and tissue remodeling. The study identifies critical factors contributing to variability and highlights the absence of standardized protocols as a major challenge. The findings suggest that optimal formulation selection should be tailored to specific clinical applications rather than adopting a universal approach. This research contributes to a deeper understanding of platelet-based therapies and provides a framework for future optimization and innovation in regenerative medicine.

Keywords: Autologous platelet formulations, platelet-rich plasma, platelet-rich fibrin, regenerative medicine, growth factors, fibrin matrix, leukocytes, tissue engineering

1. Introduction

Regenerative medicine has undergone significant transformation with the introduction of biologically derived therapeutic agents that promote natural healing mechanisms. Among these, autologous platelet formulations have gained prominence due to their safety profile, biological compatibility, and therapeutic efficacy. These formulations are derived from the patient's own blood and are enriched with platelets that release growth factors essential for cellular proliferation, angiogenesis, and tissue regeneration.

The initial development of platelet-rich plasma (PRP) marked a milestone in this field. PRP was designed to concentrate platelets beyond physiological levels, thereby enhancing the availability of growth factors at the site of injury. Early studies demonstrated its effectiveness in bone grafting and wound healing applications (Marx et al., 1998). However, limitations such as rapid degradation and inconsistent preparation methods necessitated further advancements.

Subsequent innovations led to the development of second-generation formulations, including platelet-rich fibrin (PRF). Unlike PRP, PRF does not require anticoagulants and forms a fibrin matrix that acts as a scaffold for cellular migration and sustained growth factor release (Dohan et al., 2006). This shift from liquid to fibrin-based formulations introduced significant structural and functional variability.

The variability among successive formulations arises from differences in preparation protocols, including centrifugation speed, duration, and activation techniques. These factors influence the distribution of platelets, leukocytes, and fibrin networks, ultimately affecting biological performance. For example, low-speed centrifugation techniques have been shown to preserve cellular integrity and enhance regenerative potential (Choukroun and Ghanaati, 2018).

Functional variability is equally important, as it determines the clinical effectiveness of these formulations. Growth factor release kinetics, inflammatory modulation, and cellular interactions vary significantly across different formulations. Understanding these differences is essential for selecting the appropriate formulation for specific clinical applications.

The objective of this study is to systematically evaluate the structural and functional variability of successive autologous platelet formulations. By integrating findings from existing research, this paper aims to provide a comprehensive understanding of the factors influencing variability and their implications for clinical practice.

Table 1: Comparison of PRP and PRF

Feature	PRP (Platelet-Rich Plasma)	PRF (Platelet-Rich Fibrin)
Generation	First generation	Second generation
Form	Liquid	Fibrin matrix
Anticoagulant	Required	Not required
Growth Factor Release	Rapid	Sustained
Structure	Loose	Dense fibrin network
Clinical Use	Acute conditions	Chronic healing

2. Literature Review

The evolution of autologous platelet formulations has been extensively documented in scientific literature. Early research by Marx et al. (1998) established the role of PRP in enhancing bone regeneration through growth factor delivery. This foundational study highlighted the potential of platelet-based therapies in clinical applications.

Further investigations focused on optimizing preparation methods. Fijnheer et al. (1990) demonstrated that different preparation techniques result in varying levels of platelet activation, which directly affects biological activity. Cavallo et al. (2016) emphasized that activation methods influence the release of bioactive molecules, underscoring the importance of standardized protocols.

The introduction of PRF represented a significant advancement. Choukroun et al. (2001) described PRF as a second-generation platelet concentrate with a fibrin matrix that enables sustained release of growth factors. Dohan et al. (2006) further elaborated on its structural complexity and biological advantages.

Classification systems were developed to categorize platelet formulations based on their composition. Dohan Ehrenfest et al. (2009) proposed a widely accepted classification that distinguishes between pure PRP, leukocyte-rich PRP, pure PRF, and leukocyte-rich PRF. This classification highlights the importance of cellular components in determining functional outcomes.

The role of leukocytes has been a subject of debate. Studies indicate that leukocytes contribute to immune regulation and inflammatory responses (Gudbrandsdottir et al., 2013; Carestia et al., 2019). However, excessive leukocyte activity may lead to adverse inflammatory effects.

Growth factor release kinetics is another critical factor. Kobayashi et al. (2016) demonstrated that PRF provides a more sustained release compared to PRP. Miron et al. (2020) evaluated multiple preparation protocols and highlighted the impact of centrifugation parameters on growth factor release.

Recent advancements include low-speed centrifugation techniques and injectable PRF. Choukroun and Ghanaati (2018) showed that reduced centrifugation force enhances the preservation of growth factors and cellular components. However, variability in preparation methods remains a significant challenge (Sundman et al., 2011; Steller et al., 2019).

3. Conceptual Framework of Autologous Platelet Formulations

Autologous platelet formulations can be understood through a framework that integrates structural components and functional outcomes. The primary components include platelets, leukocytes, fibrin matrix, and plasma proteins. Each component contributes to the overall biological activity of the formulation.

The structural framework is determined by preparation protocols. Centrifugation parameters influence the separation of blood components, resulting in different concentrations of platelets and leukocytes. The presence or absence of anticoagulants affects fibrin polymerization, leading to variations in matrix structure.

Functional outcomes are influenced by the release of growth factors and cytokines. Platelets release growth factors such as PDGF, TGF-β, and VEGF, which promote tissue regeneration. Leukocytes contribute to immune regulation and inflammation. The fibrin matrix acts as a scaffold that supports cellular migration and proliferation.

4. Structural Variability Across Successive Formulations

Structural variability is a defining characteristic of successive autologous platelet formulations. PRP is typically a liquid formulation with a relatively loose fibrin network. In contrast, PRF forms a dense fibrin matrix that provides structural support for tissue regeneration.

The inclusion of leukocytes further differentiates formulations. Leukocyte-rich formulations contain higher levels of white blood cells, which influence inflammatory responses. Studies have shown that leukocyte inclusion enhances antimicrobial activity but may also increase inflammation (Carestia et al., 2019).

Centrifugation parameters play a critical role in determining structure. High-speed centrifugation results in compact platelet layers, whereas low-speed techniques preserve cellular integrity and enhance fibrin network formation (Choukroun and Ghanaati, 2018).

5. Functional Variability and Biological Performance

Functional variability is primarily determined by growth factor release kinetics and cellular interactions. PRP releases growth factors rapidly, making it suitable for applications requiring immediate therapeutic effects. In contrast, PRF provides sustained release, which is beneficial for long-term tissue regeneration (Kobayashi et al., 2016).

Leukocytes influence functional outcomes by modulating inflammatory responses. Activated platelets have been shown to enhance anti-inflammatory cytokine secretion while reducing pro-inflammatory signals (Gudbrandsdottir et al., 2013).

Cellular composition also affects stem cell differentiation and tissue repair. Platelet-derived growth factors play a crucial role in

musculoskeletal regeneration (Qian et al., 2017). Additionally, mesenchymal stem cells contribute to wound healing processes (Maxson et al., 2012).

6. Influence of Preparation Protocols

Preparation protocols significantly impact both structural and functional variability. Activation methods, such as the use of thrombin or calcium chloride, influence the release of growth factors (Cavallo et al., 2016). Centrifugation speed and duration determine the distribution of cellular components.

Low-speed centrifugation has been shown to enhance the preservation of growth factors and cellular components (Choukroun and Ghanaati, 2018). However, variability in protocols remains a challenge, leading to inconsistent clinical outcomes (Sundman et al., 2011).

Table 2: Effect of Preparation Variables on Platelet Formulations

Parameter	Impact on Structure	Impact on Function
Centrifugation Speed	Cell separation changes	Affects growth factor release
Centrifugation Time	Alters concentration	Influences effectiveness
Activation Method	Modifies fibrin formation	Controls release kinetics
Leukocyte Inclusion	Changes matrix composition	Affects inflammation
Anticoagulant Use	Prevents clot formation	Alters biological activity

7. Clinical Implications and Applications

Autologous platelet formulations are widely used in various clinical applications, including orthopedics, dentistry, and wound healing. PRP is commonly used for bone grafting and sports injuries, while PRF is preferred for periodontal and implant procedures.

The choice of formulation depends on the clinical context. Rapid-release formulations are suitable for acute injuries, whereas sustained-release formulations are ideal for chronic conditions. Understanding variability is essential for optimizing clinical outcomes.

8. Results

The analysis of successive autologous platelet formulations reveals significant structural and functional variability influenced by preparation techniques, cellular composition, and fibrin architecture. One of the primary findings is that centrifugation parameters play a decisive role in determining both the qualitative and quantitative composition of platelet concentrates. High-speed centrifugation tends to produce formulations with higher platelet concentration but reduced cellular diversity, whereas low-speed centrifugation preserves leukocytes and enhances fibrin network integrity.

Another key observation is the distinction in growth factor release kinetics between formulations. First-generation formulations demonstrate rapid and short-lived release of bioactive molecules, while second-generation and advanced formulations exhibit sustained release profiles. This sustained release is associated with the presence of a dense fibrin matrix, which acts as a reservoir for growth factors and facilitates prolonged biological activity.

The inclusion of leukocytes introduces additional variability. Leukocyte-rich formulations are associated with enhanced immune modulation and antimicrobial activity, but they may also contribute to increased inflammatory responses. This dual effect highlights the importance of balancing cellular components to achieve optimal therapeutic outcomes.

Furthermore, activation methods significantly influence functional performance. Chemical activation leads to immediate growth factor release, whereas natural activation within fibrin matrices supports gradual release. This difference impacts clinical applications, particularly in distinguishing between acute and chronic treatment strategies.

Overall, the findings indicate that structural characteristics such as fibrin density, platelet concentration, and leukocyte presence are closely linked to functional outcomes. Variability across

formulations is not merely a limitation but also an opportunity for tailored therapeutic approaches.

9. Discussion

The findings of this study underscore the complexity and variability inherent in autologous platelet formulations. The relationship between structural properties and functional outcomes is multifaceted, with multiple factors interacting to influence therapeutic efficacy. The distinction between rapid and sustained growth factor release highlights the importance of selecting appropriate formulations based on clinical requirements.

The role of leukocytes remains a critical area of discussion. While their contribution to immune regulation is beneficial, excessive inflammatory responses may hinder tissue regeneration. This duality suggests that formulation design should consider the specific needs of the target tissue and the stage of healing.

The lack of standardized preparation protocols is a significant challenge. Variability in centrifugation parameters, activation methods, and handling techniques leads to inconsistent results across studies. This inconsistency limits the comparability of findings and complicates clinical decision-making.

Comparisons with existing literature reveal both alignment and divergence. While most studies agree on the advantages of fibrin-based formulations, there is ongoing debate regarding the optimal composition and preparation methods. This highlights the need for further research and standardization.

10. Conclusion

This study provides a comprehensive assessment of structural and functional variability in successive autologous platelet formulations. The findings demonstrate that variability is influenced by multiple factors, including preparation protocols, cellular composition, and fibrin architecture. Understanding these factors is essential for optimizing clinical outcomes and advancing regenerative medicine.

The research highlights the importance of tailored approaches, where formulation selection is based on specific clinical needs rather than a one-size-fits-all strategy. Future research should focus on standardizing preparation protocols and exploring innovative techniques to enhance therapeutic efficacy.

References

1. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529-535.
2. Antich-Rossello M, Forteza-Genestra MA, Monjo M, Ramis JM. Platelet-derived extracellular vesicles for regenerative medicine. Int J Mol Sci. 2021;22:8580.
3. Carestia A, Mena HA, Olexen CM, et al. Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice. Cell Rep. 2019;28(4):896-908.
4. Castro AB, Andrade C, Li X, Pinto N, Teughels W, Quirynen M. Impact of g force and timing on the characteristics of platelet-rich fibrin matrices. Sci Rep. 2021;11:6038.
5. Cavallo C, Roffi A, Grigolo B, et al. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016;2016:6591717.
6. Chemali M, Laurent A, Scaletta C, et al. Burn center organization and cellular therapy integration: managing risks and costs. J Burn Care Res. 2021;42:911-924.
7. Choukroun J, Adda F, Schoeffer C, Vervelle A. PRF: une opportunité en paro-implantologie. Implant Dent. 2001;42:55-62.
8. Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018;44:87-95.
9. Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular. 2008;16 Suppl 1:S29-S36.
10. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37-e44.
11. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e51-e55.
12. Dohan Ehrenfest DM, Bielecki T, Jimbo R, et al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012;13:1145-1152.

13. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158-167.
14. Fijnheer R, Pietersz RN, de Korte D, et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion. 1990;30:634-638.
15. Fiorentino S, Roffi A, Filardo G, Marcacci M, Kon E. European definitions, current use, and EMA stance of platelet-rich plasma in sports medicine. J Knee Surg. 2015;28:51-54.
16. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89:219-229.
17. Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol. 2013;191:4059-4067.
18. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016;20:2353-2360.
19. Linke B, Schreiber Y, Picard-Willems B, et al. Activated platelets induce an anti-inflammatory response of monocytes/macrophages through cross-regulation of PGE(2) and cytokines. Mediators Inflamm. 2017;2017:1463216.
20. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638-646.
21. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012;1:142-149.
22. Miron RJ, Chai J, Fujioka-Kobayashi M, Sculean A, Zhang Y. Evaluation of 24 protocols for the production of platelet-rich fibrin. BMC Oral Health. 2020; 20:310.
23. Qian Y, Han Q, Chen W, et al. Platelet-rich plasma derived growth factors contribute to stem cell differentiation in musculoskeletal regeneration. Front Chem. 2017;5:89.
24. Sánchez-González DJ, Méndez-Bolaina E, Fau-Trejo-Bahena NI, Trejo-Bahena NI. Platelet-rich plasma peptides: key for regeneration. Int J Pept. 2012;2012:532519.
25. Schar MO, Diaz-Romero J, Kohl S, Zumstein MA, Nesic D. Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015;473:1635-1643.
26. Sharif PS, Abdollahi M. The role of platelets in bone remodeling. Inflamm Allergy Drug Targets. 2010;9:393-399.
27. Steller D, Herbst N, Pries R, Juhl D, Hakim SG. Impact of incubation method on the release of growth factors in non-Ca(2+)-activated PRP, Ca(2+)-activated PRP, PRF and A-PRF. J Craniomaxillofac Surg. 2019;47:365-372.
28. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39:2135-2140.
29. Wang X, Fok MR, Pelekos G, Jin L, Tonetti MS. In vitro and ex vivo kinetic release profile of growth factors and cytokines from leucocyte- and platelet-rich fibrin (L-PRF) preparations. Cell. 2022;11:2089.
30. Weibrich G, Kleis WK, Hafner G. Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system. Int J Oral Maxillofac Implants. 2002;17:184-190.
31. Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants. 2005; 20:118-123.